Caplin Point Laboratories Limited

NSEI:CAPLIPOINT Stock Report

Market Cap: ₹198.9b

Caplin Point Laboratories Future Growth

Future criteria checks 2/6

Caplin Point Laboratories is forecast to grow earnings and revenue by 11.8% and 12.4% per annum respectively. EPS is expected to grow by 11.9% per annum. Return on equity is forecast to be 17% in 3 years.

Key information

11.8%

Earnings growth rate

11.88%

EPS growth rate

Pharmaceuticals earnings growth16.2%
Revenue growth rate12.4%
Future return on equity16.95%
Analyst coverage

Low

Last updated04 Jul 2026

Recent future growth updates

Analysis Article • May 18

Earnings Update: Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

It's been a good week for Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) shareholders, because the company has...
Analysis Article • Nov 10

₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results

As you might know, Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) recently reported its quarterly numbers. It was...
Analysis Article • Aug 11

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Shareholders might have noticed that Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) filed its quarterly result...

Recent updates

Analysis Article • Feb 12

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Share Price Not Quite Adding Up

It's not a stretch to say that Caplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) price-to-earnings (or "P/E...
Analysis Article • Dec 05

Do Caplin Point Laboratories' (NSE:CAPLIPOINT) Earnings Warrant Your Attention?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysis Article • Nov 09

Getting In Cheap On Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Unlikely

There wouldn't be many who think Caplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) price-to-earnings (or "P/E...
Analysis Article • Sep 16

We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise

Key Insights Caplin Point Laboratories will host its Annual General Meeting on 22nd of September CEO Sridhar Ganesan's...
Analysis Article • Aug 31

Do Caplin Point Laboratories' (NSE:CAPLIPOINT) Earnings Warrant Your Attention?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analysis Article • Aug 06

Earnings Not Telling The Story For Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

NSEI:CAPLIPOINT 1 Year Share Price vs Fair Value Explore Caplin Point Laboratories's Fair Values from the Community and...
Analysis Article • May 18

Earnings Update: Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

It's been a good week for Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) shareholders, because the company has...
Analysis Article • Apr 14

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analysis Article • Jan 28

Some Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Shareholders Look For Exit As Shares Take 27% Pounding

The Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) share price has softened a substantial 27% over the previous...
Analysis Article • Dec 01

Investor Optimism Abounds Caplin Point Laboratories Limited (NSE:CAPLIPOINT) But Growth Is Lacking

It's not a stretch to say that Caplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) price-to-earnings (or "P/E...
Analysis Article • Nov 10

₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results

As you might know, Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) recently reported its quarterly numbers. It was...
Analysis Article • Oct 31

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analysis Article • Sep 12

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50

The board of Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) has announced that it will pay a dividend on the 30th...
Analysis Article • Aug 11

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Shareholders might have noticed that Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) filed its quarterly result...
Analysis Article • Aug 10

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50

The board of Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) has announced that it will pay a dividend of ₹2.50...
Analysis Article • Jul 12

Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings

Caplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) price-to-earnings (or "P/E") ratio of 25.2x might make it look...
Analysis Article • May 24

Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues

Caplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) robust recent earnings didn't do much to move the stock. However...
Analysis Article • May 04

Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Analysis Article • Mar 07

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement

When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 31x, you may consider Caplin...
Analysis Article • Oct 24

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analysis Article • Sep 15

Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise

Key Insights Caplin Point Laboratories will host its Annual General Meeting on 21st of September CEO Sridhar Ganesan's...
Analysis Article • Aug 11

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50

Caplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) dividend will be increasing from last year's payment of the same...
Analysis Article • Sep 23

We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise

The impressive results at Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) recently will be great news for...
Analysis Article • Sep 11

Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year

The board of Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) has announced that it will be paying its dividend of...
Analysis Article • Jul 22

Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysis Article • May 15

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00

The board of Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) has announced that the dividend on 11th of June will...
Analysis Article • Jan 21

A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

Today we will run through one way of estimating the intrinsic value of Caplin Point Laboratories Limited...

Earnings and Revenue Growth Forecasts

NSEI:CAPLIPOINT - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202828,0538,1255,4137,6632
3/31/202724,8807,1285,5017,5792
3/31/202621,8726,4122,7515,232N/A
12/31/202520,9166,137N/AN/AN/A
9/30/202520,4185,8882,9215,003N/A
6/30/202519,8875,651N/AN/AN/A
3/31/202519,3965,3632,4094,324N/A
12/31/202418,9035,153N/AN/AN/A
9/30/202418,3284,9362,3103,748N/A
6/30/202417,5774,776N/AN/AN/A
3/31/202416,9614,5711,7263,184N/A
12/31/202316,3184,376N/AN/AN/A
9/30/202315,6834,1793992,593N/A
6/30/202315,1573,947N/AN/AN/A
3/31/202314,6833,7637792,714N/A
12/31/202214,1823,532N/AN/AN/A
9/30/202213,7243,3072,3053,467N/A
6/30/202213,1533,140N/AN/AN/A
3/31/202212,7102,9982,4563,367N/A
12/31/202112,0992,872N/AN/AN/A
9/30/202111,5812,7671,2882,044N/A
6/30/202111,2172,586N/AN/AN/A
3/31/202110,6242,4231,9532,686N/A
12/31/20209,9862,248N/AN/AN/A
9/30/20209,5242,1891,6501,877N/A
6/30/20209,1072,193N/AN/AN/A
3/31/20208,6402,150-321447N/A
12/31/20198,3562,159N/AN/AN/A
9/30/20197,6642,032N/A830N/A
6/30/20196,9481,894N/AN/AN/A
3/31/20196,4901,766N/A834N/A
12/31/20186,0481,621N/AN/AN/A
9/30/20185,8741,538N/AN/AN/A
6/30/20185,6281,459N/AN/AN/A
3/31/20185,3991,448N/A665N/A
12/31/20175,1451,430N/AN/AN/A
9/30/20174,7571,297N/AN/AN/A
6/30/20174,4011,165N/AN/AN/A
3/31/20174,016956N/A676N/A
12/31/20163,655783N/AN/AN/A
9/30/20163,420703N/AN/AN/A
6/30/20163,238619N/AN/AN/A
3/31/20163,088584N/A565N/A
12/31/20152,906535N/AN/AN/A
9/30/20152,722465N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CAPLIPOINT's forecast earnings growth (11.8% per year) is above the savings rate (6.9%).

Earnings vs Market: CAPLIPOINT's earnings (11.8% per year) are forecast to grow slower than the Indian market (16.3% per year).

High Growth Earnings: CAPLIPOINT's earnings are forecast to grow, but not significantly.

Revenue vs Market: CAPLIPOINT's revenue (12.4% per year) is forecast to grow faster than the Indian market (11.1% per year).

High Growth Revenue: CAPLIPOINT's revenue (12.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CAPLIPOINT's Return on Equity is forecast to be low in 3 years time (17%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/13 19:15
End of Day Share Price 2026/07/13 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Caplin Point Laboratories Limited is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rohit Bhat360 ONE Capital Market Private Limited
Siddhant KhandekarICICIdirect.com